ZA953051B - 3,5-disubstituted tetrahydro uran-2-ones - Google Patents

3,5-disubstituted tetrahydro uran-2-ones

Info

Publication number
ZA953051B
ZA953051B ZA953051A ZA953051A ZA953051B ZA 953051 B ZA953051 B ZA 953051B ZA 953051 A ZA953051 A ZA 953051A ZA 953051 A ZA953051 A ZA 953051A ZA 953051 B ZA953051 B ZA 953051B
Authority
ZA
South Africa
Prior art keywords
opt
substd
alkylene
cooh
mono
Prior art date
Application number
ZA953051A
Other languages
English (en)
Inventor
Richard Goeschke
Peter Herold
Pascal Rigollier
Juergen Klaus Maibaum
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA953051(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA953051B publication Critical patent/ZA953051B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA953051A 1994-04-18 1995-04-13 3,5-disubstituted tetrahydro uran-2-ones ZA953051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18

Publications (1)

Publication Number Publication Date
ZA953051B true ZA953051B (en) 1995-10-18

Family

ID=4204102

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA953051A ZA953051B (en) 1994-04-18 1995-04-13 3,5-disubstituted tetrahydro uran-2-ones
ZA953052A ZA953052B (en) 1994-04-18 1995-04-13 Alpha-aminoalkannic acids and reduction products
ZA953050A ZA953050B (en) 1994-04-18 1995-04-13 Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA953052A ZA953052B (en) 1994-04-18 1995-04-13 Alpha-aminoalkannic acids and reduction products
ZA953050A ZA953050B (en) 1994-04-18 1995-04-13 Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides

Country Status (26)

Country Link
US (5) US5559111A (cs)
EP (1) EP0678503B1 (cs)
JP (1) JP3240322B2 (cs)
KR (1) KR100353779B1 (cs)
CN (2) CN1266118C (cs)
AT (1) ATE183997T1 (cs)
AU (1) AU699616B2 (cs)
BR (1) BR1100656A (cs)
CA (1) CA2147056C (cs)
CY (4) CY2208B1 (cs)
CZ (1) CZ287935B6 (cs)
DE (4) DE122009000020I1 (cs)
DK (1) DK0678503T3 (cs)
ES (1) ES2137478T3 (cs)
FI (1) FI118336B (cs)
GR (1) GR3031997T3 (cs)
HU (2) HUT71701A (cs)
IL (1) IL113403A (cs)
LU (2) LU91373I2 (cs)
MY (1) MY119161A (cs)
NL (2) NL300296I2 (cs)
NO (4) NO310410B1 (cs)
NZ (1) NZ270936A (cs)
RU (1) RU95105970A (cs)
TW (2) TW366341B (cs)
ZA (3) ZA953051B (cs)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
HUP0100472A3 (en) * 1997-12-16 2003-03-28 Warner Lambert Co Novel amines as pharmaceutical agents
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
EP1200384B1 (de) * 1999-07-29 2004-04-28 Speedel Pharma AG 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung
AU2001273762A1 (en) * 2000-07-03 2002-01-14 Speedel Pharma Ag Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
CN100482636C (zh) 2000-07-05 2009-04-29 斯皮德尔药品公司 取代的辛酰胺的制备方法
TR200401871T4 (tr) * 2000-07-25 2004-08-23 Speedel Pharma Ag Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60123911T2 (de) 2000-12-14 2007-05-31 Speedel Pharma Ag Verfahren zur Herstellung von Aryloctanoyl-amiden
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
DE60235374D1 (de) 2001-05-15 2010-04-01 Novartis Ag Verfahren zur herstellung von substituierten carbonsäureestern mittels enzymatischer hydrolyse
WO2002100820A1 (en) * 2001-06-11 2002-12-19 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of alzheimer's disease
CN1571668A (zh) * 2001-10-18 2005-01-26 诺瓦提斯公司 At1－受体拮抗剂和心血管药物形成的盐
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
CN1655819A (zh) * 2002-05-17 2005-08-17 诺瓦提斯公司 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003237546A1 (en) * 2002-06-11 2003-12-22 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED Omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
US20060154926A1 (en) * 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
AU2003288899B2 (en) * 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
AU2003293155A1 (en) * 2002-11-27 2004-06-23 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MXPA06002188A (es) * 2003-08-25 2006-04-27 Warner Lambert Co Nuevos compuestos antimicrobianos de ariloxazolidinona.
CN102260188A (zh) 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
JP2007518768A (ja) * 2004-01-22 2007-07-12 ノバルティス アクチエンゲゼルシャフト 有機化合物の組み合わせ物
PL1756037T3 (pl) * 2004-01-23 2011-05-31 Novartis Ag Pochodne aminoalkoholi i ich aktywność jako inhibitory reniny
AR047447A1 (es) * 2004-01-23 2006-01-18 Speedel Experimenta Ag Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
WO2005089731A2 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1725530A1 (en) * 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
EP1724259A1 (en) * 2004-03-19 2006-11-22 Speedel Experimenta AG 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
ATE551052T1 (de) 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
WO2006083924A1 (en) * 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
WO2006095020A1 (en) * 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
JP4763771B2 (ja) * 2005-03-17 2011-08-31 ビーエーエスエフ ソシエタス・ヨーロピア 光学活性３−フェニルプロピオン酸誘導体を生成する方法、およびその誘導体の後続生成物
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
EP1904469B1 (en) * 2005-07-11 2011-09-21 Novartis AG New pyrocatechin derivatives
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
AU2006272348B2 (en) 2005-07-22 2011-06-16 Merck Frosst Canada Ltd Renin inhibitors
ES2328630T3 (es) * 2005-09-17 2009-11-16 Novartis Ag Derivados de 5-amino-4-hydroxi-7-(imidazo (1,2-a>)piridin-6- ilmetil-8-metil-nonamida y compuestos relacionados como inhibidores de la renina para el tratamiento de la hipertension.
WO2007031557A2 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
GB0519764D0 (en) 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
CA2626568A1 (en) * 2005-10-18 2007-04-26 Nicox S.A. Renin inhibitors nitroderivatives
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
WO2007123718A1 (en) * 2006-03-31 2007-11-01 Vitae Pharmaceuticals, Inc. 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES
KR20080108515A (ko) * 2006-04-03 2008-12-15 노파르티스 아게 고혈압의 치료를 위한 레닌 억제제
BRPI0713116A2 (pt) 2006-06-23 2012-10-16 Daiichi Sankyo Co Ltd composto, composição farmacêutica, uso do composto, e, método para tratar ou prevenir uma doença
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200815324A (en) * 2006-06-23 2008-04-01 Daiichi Sankyo Co Ltd Straight chain amine compound
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
US8119841B2 (en) * 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate
CN101528672A (zh) * 2006-11-09 2009-09-09 诺瓦提斯公司 阿利吉仑乳清酸盐
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
AR065792A1 (es) * 2007-03-21 2009-07-01 Speedel Experimenta Ag Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
NZ579792A (en) * 2007-04-03 2012-03-30 Novartis Ag Processes for preparing lactone compounds
EP2173696A1 (en) * 2007-07-11 2010-04-14 DSM IP Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
AU2008303504C1 (en) 2007-09-28 2013-05-16 Novartis Ag Galenical formulations of Aliskiren
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
KR101564793B1 (ko) 2007-11-05 2015-10-30 노파르티스 아게 고지질혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃｅｔｐ 억제제로서의 4-벤질아미노-1-카르복시아실-피페리딘 유도체
BRPI0822652A2 (pt) 2007-11-13 2015-06-23 Teva Pharmáceutica Ind Ltd Petach Tirva 49131 Fórmulas polimórficas de hemifumarato de alisquireno e processos para a sua preparação
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
JP5421282B2 (ja) 2007-12-03 2014-02-19 ノバルティス アーゲー 高脂血症または動脈硬化症のような疾患の処置に有用なｃｅｔｐ阻害剤としての１，２−二置換−４−ベンジルアミノ−ピロリジン誘導体
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
KR101164300B1 (ko) 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
WO2009125981A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
CN102036948A (zh) * 2008-05-23 2011-04-27 特瓦制药工业有限公司 阿利吉仑单富马酸盐及其制备方法
WO2009149344A2 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
MA33060B1 (fr) 2009-01-28 2012-02-01 Novartis Ag Formulations galéniques de composés organiques
WO2010089105A2 (en) 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
CA2724152A1 (en) 2009-02-05 2010-08-12 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
US20120009257A1 (en) 2009-03-20 2012-01-12 Indrajit Ghosh Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren
KR20110129482A (ko) 2009-03-20 2011-12-01 노파르티스 아게 알리스키렌을 포함하는 제약 조성물
WO2010112482A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
CN102686556A (zh) * 2009-08-11 2012-09-19 诺瓦提斯公司 内酯和内酰胺的开环
US20120220663A1 (en) 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
JP2013510145A (ja) * 2009-11-09 2013-03-21 メディヴィル・アクチエボラーグ １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
EP2523934A1 (en) * 2010-02-10 2012-11-21 Ratiopharm GmbH Salts of aliskiren
TW201136582A (en) 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
PL2630118T3 (pl) 2010-10-19 2015-04-30 Mylan Laboratories Ltd Synteza Aliskirenu
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en) 2011-10-25 2013-05-02 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
WO2013121443A1 (en) 2012-02-17 2013-08-22 Mylan Laboratories Ltd. An improved process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
CA2873869A1 (en) 2012-05-11 2013-11-14 Novartis Ag Dispensing device
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
CN105377858B (zh) * 2013-06-27 2017-11-21 帕西昂奥地利有限两合公司 利用流化床制备格氏试剂
US11081240B2 (en) 2018-06-14 2021-08-03 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
EP0678503A1 (de) 1995-10-25
NL300296I1 (nl) 2007-12-03
US5627182A (en) 1997-05-06
TW402582B (en) 2000-08-21
ES2137478T3 (es) 1999-12-16
AU699616B2 (en) 1998-12-10
IL113403A (en) 2001-07-24
DE122009000020I1 (de) 2009-08-06
US5654445A (en) 1997-08-05
CN1550491A (zh) 2004-12-01
NO2011020I1 (no) 2011-09-26
FI951771A0 (fi) 1995-04-12
JPH0881430A (ja) 1996-03-26
MY119161A (en) 2005-04-30
CY2007027I1 (el) 2009-11-04
EP0678503B1 (de) 1999-09-01
CY2208B1 (en) 2002-11-08
BR1100656A (pt) 2000-06-06
US5646143A (en) 1997-07-08
FI118336B (fi) 2007-10-15
HU9501076D0 (en) 1995-06-28
DE122007000071I2 (de) 2009-01-02
CA2147056A1 (en) 1995-10-19
GR3031997T3 (en) 2000-03-31
CY2009006I2 (el) 2010-07-28
HUT74074A (en) 1996-10-28
NO2009011I1 (no) 2009-06-02
RU95105970A (ru) 1997-01-10
DK0678503T3 (da) 2000-03-20
US5705658A (en) 1998-01-06
NO951441D0 (no) 1995-04-12
NO2009011I2 (no) 2010-11-22
DE122007000071I1 (de) 2008-01-31
KR100353779B1 (ko) 2003-01-08
KR950032037A (ko) 1995-12-20
FI951771A7 (fi) 1995-10-19
CY2011015I1 (el) 2014-04-09
CZ287935B6 (cs) 2001-03-14
JP3240322B2 (ja) 2001-12-17
LU91373I2 (fr) 2007-12-31
CZ97695A3 (en) 1995-11-15
NL300386I1 (nl) 2009-07-01
CY2007027I2 (el) 2009-11-04
HU226860B1 (en) 2009-12-28
DE122011100052I1 (de) 2012-01-19
NO2007011I2 (cs) 2011-07-25
US5559111A (en) 1996-09-24
NO951441L (no) 1995-10-19
CA2147056C (en) 2005-10-25
CY2009006I1 (el) 2010-07-28
NO310410B1 (no) 2001-07-02
NO2007011I1 (no) 2007-12-11
ZA953052B (en) 1995-10-18
TW366341B (en) 1999-08-11
NZ270936A (en) 1997-06-24
HUT71701A (en) 1996-01-29
HK1070881A1 (en) 2005-06-30
CN1117960A (zh) 1996-03-06
CY2011015I2 (el) 2014-04-09
LU91564I2 (fr) 2009-07-06
AU1642195A (en) 1995-10-26
ATE183997T1 (de) 1999-09-15
HU9501078D0 (en) 1995-06-28
ZA953050B (en) 1995-11-08
CN1266118C (zh) 2006-07-26
NL300296I2 (nl) 2008-02-01
CN1153759C (zh) 2004-06-16
DE59506707D1 (de) 1999-10-07
IL113403A0 (en) 1995-07-31

Similar Documents

Publication Publication Date Title
ZA953051B (en) 3,5-disubstituted tetrahydro uran-2-ones
ZA881377B (en) Process for improving the photochemical stability of dyeings on polyester fibre materials
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
ES2084347T3 (es) Derivados de 5-heteroil-indol.
EP0431943A3 (en) Nitrogen-containing spirocycles
CA2027206A1 (en) Sulphonylaminocarbonyltriazolinones
TW222000B (cs)
GR3021557T3 (en) Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
EP0403062A3 (en) Tickened acidic liquid composition with amine fwa useful as a bleaching agent vehicle
DK0953563T3 (da) Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor
PT90831A (pt) Processo para a preparacao de eteres da 2-amino-7-hidroxitetralina
ATE118214T1 (de) Salze von 3-(cis-2,6-dimethylpiperidino)- sydnonimin.